A Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome

This study has been completed.
Information provided by (Responsible Party):
NPS Pharma
ClinicalTrials.gov Identifier:
First received: September 23, 2013
Last updated: May 6, 2015
Last verified: May 2015

This will be an open label, 4-cohort study. Non-randomized subjects will receive teduglutide in each of the 3 active cohorts. An attempt will be made to enroll additional subjects into an observational cohort who will receive standard of care. Three doses of teduglutide are to be investigated for 12 weeks. All subjects will be screened prior to the start of treatment (SOT) to establish baseline characteristics including safety, eligibility and nutritional support parameters.

Condition Intervention Phase
Short Bowel Syndrome
Drug: teduglutide
Phase 3

Study Type: Interventional
Study Design: Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A 12-Week Pharmacokinetic, Safety, and Pharmacodynamic Study of Teduglutide in Pediatric Subjects Aged 1 Year Through 17 Years, With Short Bowel Syndrome Who Are Dependent on Parenteral Support

Resource links provided by NLM:

Further study details as provided by NPS Pharma:

Primary Outcome Measures:
  • Safety [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Number of reported adverse events after 12 weeks of teduglutide

  • Pharmacodynamics [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Change in parenteral support requirements after 12 weeks of teduglutide (liters/week)

  • Pharmacodynamics [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]
    Change in enteral support requirements after 12 weeks of teduglutide (liters/week)

Enrollment: 42
Study Start Date: November 2013
Study Completion Date: January 2015
Primary Completion Date: January 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: teduglutide
Open label teduglutide, subcutaneously injected.
Drug: teduglutide


Ages Eligible for Study:   1 Year to 17 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Key Inclusion Criteria:

  • Current history of SBS as a result of major intestinal resection, (eg, due to necrotizing enterocolitis, midgut volvulus, intestinal atresia, or gastroschisis) for at least 12 months prior to screening
  • Short bowel syndrome that requires parenteral nutrition/intravenous (PN/IV) support
  • Stable PN/IV support for at least 3 months prior to enrollment based upon the opinion of the investigator

Key Exclusion Criteria:

  • Serial transverse enteroplasty or any other bowel lengthening procedure performed within the past 3 months
  • Unstable absorption due to cystic fibrosis, untreated Hirschsprung's disease or known DNA abnormalities (ie, Familial Adenomatous Polyposis, Fanconi syndrome)
  • Evidence of obstruction on upper gastrointestinal (GI) series done within 6 months prior to screening
  • Major gastrointestinal surgical intervention within 3 months prior to screening (insertion of feeding tube or endoscopic procedure is allowed)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01952080

  Show 19 Study Locations
Sponsors and Collaborators
NPS Pharma
Study Director: Executive Director Clinical Development, GI NPS Pharma
  More Information

No publications provided

Responsible Party: NPS Pharma
ClinicalTrials.gov Identifier: NCT01952080     History of Changes
Other Study ID Numbers: TED-C13-003
Study First Received: September 23, 2013
Last Updated: May 6, 2015
Health Authority: United States: Food and Drug Administration

Keywords provided by NPS Pharma:
Short Bowel Syndrome
Pediatric SBS

Additional relevant MeSH terms:
Short Bowel Syndrome
Digestive System Diseases
Gastrointestinal Diseases
Intestinal Diseases
Malabsorption Syndromes
Pathologic Processes
Postoperative Complications

ClinicalTrials.gov processed this record on September 02, 2015